Background Bullous pemphigoid (BP) is the most common autoimmune blistering disease
requiring treatment with immunosuppressive medications; however, finding a therapy that …

Background Bullous pemphigoid (BP) is the most common autoimmune blistering skin
disease worldwide. Systemic corticosteroids are considered the mainstay of therapy; …

The objective of this review was to critically analyze the currently available literature on the
use of rituximab to treat patients with bullous pemphigoid (BP). The focus was to highlight …

Background Rituximab, a monoclonal antibody directed against B lymphocytes, has been
found to be a therapeutic agent for severe, refractory autoimmune bullous diseases …

BACKGROUND: Rituximab induces depletion of B cells and has shown efficacy in antibody-
mediated autoimmune disorders. In studies on small series of patients with pemphigus …

Pemphigus is a life‐threatening autoimmune bullous disorder that requires long‐term
treatment with systemic corticosteroids mostly in conjunction with further …

Background Bullous pemphigoid is an autoimmune blistering skin disease that
predominantly affects the elderly. Conventional therapy using high-dose systemic …

Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of
severe allergic asthma and inhibits IgE binding to FcεRI. According to increasing evidence of …

Rituximab is a monoclonal antibody targeting CD20 on B cells with proven efficacy for
pemphigus vulgaris, now an FDA-approved indication. Other autoimmune bullous diseases …

BACKGROUND: Rituximab has been increasingly used in autoimmune blistering
dermatoses, mainly in pemphigus. However, only a few larger case series are available on …